CompletedPhase 3

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

United States316 participantsStarted 2023-09-09

Plain-language summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of motion sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI\>40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

What they're measuring

Prevention of Vomiting Measured by Vomiting Assessment (VA)

Timeframe: 1 day

Trial details

NCT IDNCT05903924

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-04-06

Results submitted2025-03-18

View on ClinicalTrials.gov More Motion Sickness trials